Brokers Offer Predictions for TPST FY2028 Earnings

Tempest Therapeutics, Inc. (NASDAQ:TPST) – Equities research analysts at William Blair issued their FY2028 earnings per share (EPS) estimates for Tempest Therapeutics in a research note issued to investors on Thursday, March 27th. William Blair analyst M. Phipps anticipates that the company will post earnings of ($1.60) per share for the year. The consensus estimate for Tempest Therapeutics’ current full-year earnings is ($1.39) per share.

Other equities analysts have also recently issued reports about the company. HC Wainwright decreased their target price on Tempest Therapeutics from $47.00 to $16.00 and set a “buy” rating on the stock in a report on Friday. Scotiabank dropped their price target on Tempest Therapeutics from $13.00 to $7.00 and set a “sector outperform” rating on the stock in a research note on Friday.

Tempest Therapeutics Stock Performance

NASDAQ TPST opened at $0.74 on Monday. Tempest Therapeutics has a 1 year low of $0.70 and a 1 year high of $6.00. The business’s fifty day moving average is $0.86 and its two-hundred day moving average is $0.97. The stock has a market capitalization of $32.21 million, a P/E ratio of -0.48 and a beta of -1.83.

Tempest Therapeutics (NASDAQ:TPST) last released its earnings results on Thursday, March 27th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.07). The company had revenue of $0.49 million for the quarter.

Hedge Funds Weigh In On Tempest Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new stake in shares of Tempest Therapeutics in the third quarter worth $34,000. Virtu Financial LLC acquired a new position in Tempest Therapeutics during the fourth quarter valued at $36,000. Northern Trust Corp lifted its stake in Tempest Therapeutics by 233.2% in the 4th quarter. Northern Trust Corp now owns 67,815 shares of the company’s stock worth $57,000 after acquiring an additional 47,461 shares in the last quarter. Millennium Management LLC acquired a new stake in Tempest Therapeutics during the 4th quarter worth about $158,000. Finally, Geode Capital Management LLC grew its stake in Tempest Therapeutics by 42.7% during the 3rd quarter. Geode Capital Management LLC now owns 220,067 shares of the company’s stock valued at $308,000 after acquiring an additional 65,826 shares in the last quarter. 22.52% of the stock is currently owned by hedge funds and other institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.